TouchIMMUNOLOGY were delighted to talk to Ken Kato at ASCO’s virtual Gastrointestinal Cancers Symposium 2021 to discuss the potential role of nivolumab in the treatment of gastrointestinal cancers, and how the identification of biomarkers is key to improve clinical response.
For more information on the 5-year follow-up data presented at ASCO’s Gastrointestinal Cancer’s Symposium, please click here.
- What is known about the immunological effects of nivolumab treatment and what remains to be elucidated? (0:31)
- What progress has been made in identifying robust biomarkers associated with clinical response to nivolumab? (2:00)
Disclosures: Ken Kato has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Share this Video
Related Videos In Immuno-oncology
Tumour-selective targeted delivery of antibody-cytokine fusion proteins: Jamie Spangler, AACR 2023
Antibody-cytokine fusion proteins are a promising immunotherapy that could overcome off-target immune cell activation and the short serum half-life associated with low-dose interleukin-2 treatment. We were delighted to talk with Dr. Jamie Spangler (Johns Hopkins University, Baltimore, MD, USA) around the rationale for fusing cytokines to anti-cytokine antibodies in targeted therapy, the improved therapeutic efficacy […]
DNA damage as a target and predictor of treatment response in immunotherapy: Sandra Demaria, AACR 2023 (Part 2)
A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. It was a pleasure to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, NY, USA) to discuss how radiation-induced DNA damage is targeted in treatment strategies with immunotherapy, […]
Radiation-induced DNA damage response and tumour immunogenicity: Sandra Demaria, AACR 2023 (Part 1)
A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. We were delighted to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, NY, USA) around the radiation-induced DNA damage response, its association with cancer and how this […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!